Expanded Access Policy

Crinetics is dedicated to developing therapies for people with endocrine diseases and endocrine-related tumors. We are currently conducting several human clinical studies to demonstrate the safety and efficacy of our drug candidates for the treatment of various conditions. Our clinical studies are intended to generate sufficient data to support marketing applications for regulatory approval by the US FDA and other regulatory authorities. 

At this time, Crinetics is not making any of its investigational drugs available on an Expanded Access basis. Crinetics believes that participation in our carefully designed clinical studies to assess safety and efficacy of our investigational therapies is the most appropriate way for patients to access our investigational products. 

Crinetics Clinical Studies: For information on Crinetics’ clinical studies that are recruiting, search “Crinetics” at clinicaltrials.gov.  

Crinetics may revise this policy in the future as the benefit-risk profile of each of our investigational drugs is evaluated based on evolving clinical data. This posting will be updated should there be any policy change. The posting of this policy shall not serve as a guarantee of access to any specific investigational medicine by any individual patient.